Vijaya Kancherla1, John L Elliott2, Birju B Patel3, N Wilson Holland2,3, Theodore M Johnson1,2,3,4, Anjali Khakharia2,3,4, Lawrence S Phillips3,5, Godfrey P Oakley1, Camille P Vaughan2,3,4. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. 2. Division of General Medicine & Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 3. Atlanta VA Medical Center, Decatur, Georgia. 4. Department of Veterans Affairs Birmingham/Atlanta Geriatric Research, Education, and Clinical Center, Atlanta, Georgia. 5. Division of Endocrinology, Lipids & Metabolism, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Abstract
OBJECTIVE: To examine the association between long-term metformin therapy and serum vitamin B12 monitoring. DESIGN: Retrospective cohort study. SETTING: A single Veterans Affairs Medical Center (VAMC), 2002-2012. PARTICIPANTS: Veterans 50 years or older with either type 2 diabetes and long-term metformin therapy (n = 3,687) or without diabetes and no prescription for metformin (n = 13,258). MEASUREMENTS: We determined diabetes status from outpatient visits, and defined long-term metformin therapy as a prescription ≥500 mg/d for at least six consecutive months. We estimated the proportion of participants who received a serum B12 test and used multivariable logistic regression, stratified by age, to evaluate the association between metformin use and serum B12 testing. RESULTS: Only 37% of older adults with diabetes receiving metformin were tested for vitamin B12 status after long-term metformin prescription. The mean B12 concentration was significantly lower in the metformin-exposed group (439.2 pg/dL) compared to those without diabetes (522.4 pg/dL) (P = .0015). About 7% of persons with diabetes receiving metformin were vitamin B12 deficient (<170 pg/dL) compared to 3% of persons without diabetes or metformin use (P = .0001). Depending on their age, metformin users were two to three times more likely not to receive vitamin B12 testing compared to those without metformin exposure, after adjusting for sex, race and ethnicity, body mass index, and number of years treated at the VAMC. CONCLUSION: Long-term metformin therapy is significantly associated with lower serum vitamin B12 concentration, yet those at risk are often not monitored for B12 deficiency. Because metformin is first line therapy for type 2 diabetes, clinical decision support should be considered to promote serum B12 monitoring among long-term metformin users for timely identification of the potential need for B12 replacement.
OBJECTIVE: To examine the association between long-term metformin therapy and serum vitamin B12 monitoring. DESIGN: Retrospective cohort study. SETTING: A single Veterans Affairs Medical Center (VAMC), 2002-2012. PARTICIPANTS: Veterans 50 years or older with either type 2 diabetes and long-term metformin therapy (n = 3,687) or without diabetes and no prescription for metformin (n = 13,258). MEASUREMENTS: We determined diabetes status from outpatient visits, and defined long-term metformin therapy as a prescription ≥500 mg/d for at least six consecutive months. We estimated the proportion of participants who received a serum B12 test and used multivariable logistic regression, stratified by age, to evaluate the association between metformin use and serum B12 testing. RESULTS: Only 37% of older adults with diabetes receiving metformin were tested for vitamin B12 status after long-term metformin prescription. The mean B12 concentration was significantly lower in the metformin-exposed group (439.2 pg/dL) compared to those without diabetes (522.4 pg/dL) (P = .0015). About 7% of persons with diabetes receiving metformin were vitamin B12 deficient (<170 pg/dL) compared to 3% of persons without diabetes or metformin use (P = .0001). Depending on their age, metformin users were two to three times more likely not to receive vitamin B12 testing compared to those without metformin exposure, after adjusting for sex, race and ethnicity, body mass index, and number of years treated at the VAMC. CONCLUSION: Long-term metformin therapy is significantly associated with lower serum vitamin B12 concentration, yet those at risk are often not monitored for B12 deficiency. Because metformin is first line therapy for type 2 diabetes, clinical decision support should be considered to promote serum B12 monitoring among long-term metformin users for timely identification of the potential need for B12 replacement.
Authors: Nancy S Chiles; Caroline L Phillips; Stefano Volpato; Stefania Bandinelli; Luigi Ferrucci; Jack M Guralnik; Kushang V Patel Journal: J Diabetes Complications Date: 2013-10-11 Impact factor: 2.852
Authors: D S Knopman; S T DeKosky; J L Cummings; H Chui; J Corey-Bloom; N Relkin; G W Small; B Miller; J C Stevens Journal: Neurology Date: 2001-05-08 Impact factor: 9.910
Authors: Jolien de Jager; Adriaan Kooy; Philippe Lehert; Michiel G Wulffelé; Jan van der Kolk; Daniël Bets; Joop Verburg; Ab J M Donker; Coen D A Stehouwer Journal: BMJ Date: 2010-05-20
Authors: M G Wulffelé; A Kooy; P Lehert; D Bets; J C Ogterop; B Borger van der Burg; A J M Donker; C D A Stehouwer Journal: J Intern Med Date: 2003-11 Impact factor: 8.989
Authors: Rebecca L Sudore; Andrew J Karter; Elbert S Huang; Howard H Moffet; Neda Laiteerapong; Yael Schenker; Alyce Adams; Rachel A Whitmer; Jennifer Y Liu; Yinghui Miao; Priya M John; Dean Schillinger Journal: J Gen Intern Med Date: 2012-08-02 Impact factor: 5.128
Authors: Monica C Serra; Vijaya Kancherla; Anjali Khakharia; Latricia L Allen; Lawrence S Phillips; Mary K Rhee; Peter W F Wilson; Camille P Vaughan Journal: Diabetes Res Clin Pract Date: 2020-10-06 Impact factor: 5.602
Authors: D Marsman; D W Belsky; D Gregori; M A Johnson; T Low Dog; S Meydani; S Pigat; R Sadana; A Shao; J C Griffiths Journal: Eur J Nutr Date: 2018-06 Impact factor: 5.614
Authors: Stacy L Longo; Jessica M Ryan; Kelsey B Sheehan; Debra J Reid; Michael P Conley; Carla J Bouwmeester Journal: Pharm Pract (Granada) Date: 2019-09-13